Literature DB >> 3881263

Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants.

E Herskovits, A Famulari, L Tamaroff, A M Gonzalez, A Vázquez, R Dominguez, H Fraiman, J Vila.   

Abstract

A comparative study of the prevention of recurrences of cerebral transient ischemic attacks during a 6-month observation period was conducted in 73 patients treated with a combination of acetylsalicylic acid and dipyridamole (ASAD, 1,050 mg + 150 mg/day) and in 65 patients treated with pentoxifylline (PTX 1,200 mg/day, Trental 400 t.d.s.). The patients were randomly assigned to the treatments. Risk factor analysis showed high prevalence of arterial hypertension, hyperlipidemia and smoking in these patients. The two groups were matched in terms of age, sex, blood pressure and site of TIA origin (carotid 63% in the ASAD, 65% in the PTX group). 23 ASAD patients and 9 PTX patients suffered a recurrence. There were 4 nonfatal stroke events with ASAD and 2 with PTX. 80 recurrent TIAs were recorded in 19 ASAD patients compared with 19 such episodes in 9 PTX subjects. The morbidity rates (life table analysis) were significantly lower (p less than 0.05) in the PTX group. The results of the study point to a preventive effect of PTX in terms of the reduction in TIA recurrences.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881263     DOI: 10.1159/000115765

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  7 in total

1.  Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system.

Authors:  A Azhar; H M El-Bassossy
Journal:  J Endocrinol Invest       Date:  2014-11-21       Impact factor: 4.256

2.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 3.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

Review 4.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 5.  Antiplatelet agents and anticoagulants for hypertension.

Authors:  Gregory Yh Lip; Dirk C Felmeden; Girish Dwivedi
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 6.  Pentoxifylline for vascular health: a brief review of the literature.

Authors:  Mark F McCarty; James H O'Keefe; James J DiNicolantonio
Journal:  Open Heart       Date:  2016-02-08

7.  Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack.

Authors:  Imama A Naqvi; Ayeesha K Kamal; Hasan Rehman
Journal:  Cochrane Database Syst Rev       Date:  2020-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.